XORTX TherapeuticsXRTX
Market Cap: $5.81M
About: XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
Employees: 3
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 [Q1] → 5 (+1) [Q2]
0.31% less ownership
Funds ownership: 0.83% [Q1] → 0.53% (-0.31%) [Q2]
56% less capital invested
Capital invested by funds: $66K [Q1] → $29.2K (-$36.7K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for XRTX.
Financial journalist opinion
Based on 4 articles about XRTX published over the past 30 days